Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 6
Submit an article Journal homepage
21
Views
0
CrossRef citations to date
0
Altmetric
Review

Economic evaluation of aromatase inhibitors for the treatment of breast cancer

Amin M Alousi Barbara Ann Karmanos Cancer Institute, Wayne State University, 4th Floor, Hudson-Webber Cancer Research Center, 4100 John R, Detroit, MI 48201, USA. [email protected]
,
Miron Stano Barbara Ann Karmanos Cancer Institute, Wayne State University, 4th Floor, Hudson-Webber Cancer Research Center, 4100 John R, Detroit, MI 48201, USA. [email protected]
&
Michael S Simon Barbara Ann Karmanos Cancer Institute, Wayne State University, 4th Floor, Hudson-Webber Cancer Research Center, 4100 John R, Detroit, MI 48201, USA. [email protected]
Pages 773-781 | Published online: 09 Jan 2014

References

  • Hillner BE. Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer. Anticancer Drugs 9(10), 843–847 (1998).
  • Hillner BE. Economic and cost- effectiveness issues in breast cancer treatment. Semin. Oncol 23(1 Suppl. 2) 98–104 (1996).
  • Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. PhatmacoEconomics 21 (6), 383–396 (2003).
  • Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. /AIWA 276(15), 1253–1258 (1996). Outstanding review of cost-efficacy research design and terminology.
  • Gold MR, Torrance PGW, Fryback DG eta]. Identifying and valuing outcomes. In: Cost-effectiveness in Health ancl Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA, 82–123 (2003).
  • Tengs TO, Adams ME, Pliskin JS etal Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15, 369–384 (2003).
  • Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Merl Dec. Making20 (3), 332–342 (2000).
  • Higa GM. New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits. PhalmacoEconomics 17(2), 121–132 (2000).
  • Buzdar AU. Anastrozole (Arimidex) in clinical practice versus the old gold standard, tamoxifen. Expert. Rev Anticancer Ther. 2(6), 623–629 (2002).
  • Lake DE, Hudis C. Aromatase inhibitors in breast cancer: an update. Cancer Con. 9(6), 490–498 (2002).
  • Wait SH. Economic evaluation of endocrine therapy in the treatment of breast cancer. Anticancer Drugs 9 (10), 849–857(1998).
  • Ingle JN. Sequencing of hormonal therapy in breast cancer. Breast J. 8(6), 332–337 (2002).
  • Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin. Cancer Res. 9(1 Pt. 2), S468—S472 (2003).
  • Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 95(9), 2006–2016 (2002).
  • MacNeill FA, Jones AL, Jacobs S, Lonning PE, Powles TJ, Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. BE j Cancer 66(4), 692–697 (1992).
  • Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl. I Merl 348(24), 2431–2442 (2003).
  • Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Clin. Oncol 20(3), 751–757 (2002).
  • Kaufmann M, Bajetta E, Dirix LY etal Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. j Clin. Oncol 18(7), 1399–1411 (2000).
  • Buzdar AU, Jonat W, Howell A etal Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Arimidex Study Group. Cancer 83(6), 1142–1152 (1998).
  • Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. 1 Clin. Oncol 19(3), 881–894 (2001).
  • Mouridsen H, Gershanovich M, Sun Y etal Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. Clin. Oncol 19(10), 596–2606 (2001).
  • Mouridsen H, Gershanovich M, Sun Y etal Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Clin. Oncol 21(11), 2101–2109 (2003).
  • ••Landmark study evaluating letrozole asfirst-line treatment for advanced breast cancer.
  • Nabholtz JM, Buzdar A, Pollak M etal Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. j Clin. Oncol 18(22), 3758–3767 (2000).
  • Bonneterre J, Thurlimann B, Robertson JF et al Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. Clin. Oncol 18(22), 3748–3757 (2000).
  • Bonneterre J, Buzdar A, Nabholtz JM etal Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9) 2247–2258 (2001). Landmark study evaluating anastrozole as first-line treatment for advanced breast cancer.
  • Veronesi U, Sacchini V, Colleoni M, Goldhirsch A. Breast cancer. In: Manual of Clinical Oncology Pollock R (Ed.). Wiley- Liss Inc., NY, USA, 491–513 (1999).
  • Johnston SR. Update on endocrine aspects of breast cancer: report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6–9 December 2000. Least Cancer Res. 3(3), 180–182 (2001).
  • Ingle JN. Adjuvant endocrine therapy in postmenopausal breast cancer. Clin. Cancer Res. 9(1 Pt. 2), S480—S485 (2003).
  • Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (9324), 2131–2139 (2002).
  • ••Pivotal study which challenged whether an aromatase inhibitors could replace tamoxifen for adjuvant treatment of early breast cancer (Anastrozole, Tarnoldfen, Alone or in Combination Trial).
  • Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Clin. Oncol 20(15), 3317–3327 (2002).
  • Duffy SRG, Jackson TL. The ATAC (Ariiex, tamoxifen, alone or in combination) early breast cancer (EBC) trial in postmenopausal (PM) patients: endometrial sub-protocol results. Proc. Am. Soc. 017C0i 21 (A40), (2002) .
  • Fallowfield L, Cella D. Assessing the quality of life (Q0L) of postmenopausal (PM) women randomized into the ATAC (Arimidex, tamoxifen, alone or in combination) adjuvant breast cancer (BC) trial. Pmc. Am. Soc. Gun. Oncol 21 (A40), (2003).
  • Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. j Clin. Oncol 21(17), 3357–3365 (2003).
  • Winer EP, Hudis C, Burstein HJ eta]. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. Gun. Oncol 21(13), 2597–2599 (2003).
  • Ueno NT, Buzdar AU, Singletary SE etal Combined-modality treatment of inflammatory breast carcinoma: 20 years of experience at M. D. Anderson Cancer Center. Cancer Chemother. Pharmacol 40(4), 321–329 (1997).
  • Eiermann W, Paepke S, Appfelstaedt J eta]. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11), 1527–1532 (2001).
  • Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J. Stemicl Biochem. Mal Biol. 79(1–5), 103–107 (2001).
  • Ellis MJ, Coop A, Singh B eta] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. j Gun. Oncol 19(18), 3808–3816 (2001).
  • Chlebowski RT, Col N, Winer EP et al American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene and aromatase inhibition. j Gun. Oncol 20(15), 3328–3343 (2002).
  • de Koning HJ, van Ineveld BM, de Haes JC etal Advanced breast cancer and its prevention by screening. BE j Cancer 65(6), 950–955 (1992).
  • Richards MA, Braysher S, Gregory WM, Rubens RD. Advanced breast cancer: use of resources and cost implications. BE J. Cancer 67 (4), 856–860 (1993) .
  • Hillner BE, Smith TJ. Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. Oncology9\(Suppl. 11), 129–134 (1995).
  • Corry JF, Lonning PE. Systemic therapy in breast cancer: efficacy and cost utility. PharmacoEconomic55(3), 198–212 (1994).
  • Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. j Gun. Oncol 18(2), 284–286 (2000).
  • Bryson HM, Plosker GL. Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer. PharmacoEconomics 4 (1), 40–66 (1993) .
  • Smith MD, McGhan WF. Financial facts about treating breast cancer. Bus. Health 14(12), 67–68 (1996).
  • Simon MS, Ibrahim D, Newman L, Stano M. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging 19(6), 453–463 (2002).
  • Ravdin P Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer. Lancet 359 (9324), 2126–2127 (2002).
  • Friedberg M, Saffran B, Stinson TJ, Nelson W Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAIVIA 282(15), 1453–1457 (1999). Examines the possible conflict of interest in drug company sponsorship of cost-effectiveness analysis studies.
  • Wright T Anastrozole cost effective in advanced breast cancer. PharmacoEcon. Outcomes News 147,3–4 (2003).
  • Nuijten M, Meester L, Waibel F, Wait S. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. PharmacoEconomics 16(4), 379–397 (1999).
  • Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91(3), 484–489 (2001).
  • Higa GM. Aromatase inhibitors for breast cancer: pharmacoeconomic considerations. Expert. Opin. Pharmacother. 2(6), 987–995 (2001).
  • ••Well-written review article on the pharrnacoeconomics of aromatase inhibitors.
  • Verma S, Rocchi A. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support. Cate Cancer 11(11)728-734 (2003).
  • Karnon J, Jones T A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. PhatmacoEconomics 21 (7), 513–525 (2003).
  • Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. j Clin. Oncol 56(3), 289–296 (2003).
  • Dranitsaris G, Leung P, Mather J, Oza A. Cost—utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer DIM'S 11(7), 591–601 (2000).

Websites

  • www.who.int/mediacentre/releases/2003 (Accessed October 2003)
  • www.cancer.org (Accessed October 2003)
  • www.seer.cancer.gov/ (Accessed October 2003)
  • www.federalreserve.gov/releases/H10/hist/ (Accessed October 2003)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.